Precigen, Inc.
PGENHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Precigen, Inc. focuses on Biotechnology services and products. Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune. At a $2.54B market cap, Precigen, Inc. ranks as a mid-cap company within healthcare. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
Market Cap
$2.54B
Beta
1.02
P/E (TTM)
—
P/E (Fwd)
-32.27
EPS (TTM)
$-1.07
EPS (Fwd)
$-0.22
ROE
-837.1%
ROA
-18.1%
Cash
$38.2M
Total Debt
$98.3M
Free CF
-$100.1M
52W Change
71.9%
Annual Financials
Cash vs Debt
Where PGEN stands vs its 150-day and 200-day moving averages
As of the September 1, 2026 close, PGEN finished 46.20% above its 150-day moving average ($4.74) and 50.98% above its 200-day moving average ($4.59). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PGEN overbought or oversold?
At the September 1, 2026 close, PGEN's RSI(14) was 51.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $38.2M in cash, though total debt stands at $98.3M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$100.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -837.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $26.9M (2022) to $9.7M (2025), a 64% decline worth watching.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Precigen, Inc.'s trajectory.